FDAapproval65% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Vigonvita Life Sciences.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Metabolism · Oral Drug Delivery
- Sub-indication
- General
Related signal: VV913 Food Effect Study Initiated by Vigonvita Life Sciences